KRIBB11 is primarily utilized in the field of cancer research due to its role as a potent and selective inhibitor of heat shock protein 90 (HSP90). This protein is crucial for the stability and function of many oncogenic client proteins, making it a significant target in the development of anticancer therapies. By inhibiting HSP90, KRIBB11 disrupts the maturation and activation of these client proteins, leading to the degradation of cancer-promoting molecules and ultimately inhibiting tumor growth and survival. Its application extends to preclinical studies where it is used to investigate the mechanisms of HSP90 inhibition and its potential therapeutic effects in various cancer models. Additionally, KRIBB11 serves as a valuable tool in understanding the role of HSP90 in cellular stress responses and protein homeostasis, contributing to advancements in molecular biology and drug discovery.